which generated $1.2 billion in sales last year and according to GlobalData could reach $9 billion by 2029. According to a recent Daiichi Sankyo business update (PDF), Dato-DXd will contribute to ...
The FDA has started a review of AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan ... NeoADAURA in the neoadjuvant setting and ADAURA 2 in the adjuvant setting – that, if positive ...
Clinical Trials Arena on MSN13d
Daiichi Sankyo and AstraZeneca’s Enhertu shows OS improvements in Phase III trialDaiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has shown clinically meaningful 'improvement' in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback